Annual Report 2002 - Roche
Annual Report 2002 - Roche
Annual Report 2002 - Roche
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
The sale of the Vitamins and Fine Chemicals Division,<br />
legal settlements with US direct customers in the<br />
vitamin case and an impairment of financial assets<br />
result in significant one-time charges and a substantial<br />
consolidated net loss<br />
Pharmaceuticals and Diagnostics Divisions grow faster<br />
than the global market<br />
Sales by core Group businesses up by 9% in local<br />
currencies and by 3% in Swiss francs<br />
Double-digit rise in operating profit and another<br />
increase in margins<br />
Strong cash flow and solid balance sheet<br />
Quantum leap forward in Japan as a result of Chugai<br />
alliance<br />
Pegasys approved worldwide for hepatitis C;<br />
pharmaceuticals pipeline substantially strengthened<br />
Diagnostics business expands global market lead<br />
Double-digit sales growth and stable operating profit<br />
margin expected for 2003<br />
Results on an adjusted basis